CAS 1622849-43-7

GSK3145095

CAS : 1622849-43-7

GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.

Formule : C₂₀H₁₇F₂N₅O₂

Degré de pureté : 99.50%

Couleur et forme : Solid

Masse moléculaire : 397.38

Ref: TM-T15437

GSK 3145095

CAS : 1622849-43-7

Formule : C₂₀H₁₇F₂N₅O₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 397.3781

Ref: IN-DA01V3KM

GSK3145095

CAS : 1622849-43-7

GSK3145095

Degré de pureté : ≥98%

Masse moléculaire : 397.38g/mol

Ref: 54-BUP04454

GSK3145095

CAS : 1622849-43-7

GSK3145095 is a small molecule inhibitor, which is a synthetic compound developed by GlaxoSmithKline. It functions as a targeted inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a crucial mediator in the signaling pathways that control inflammation and cell death. The source of GSK3145095 is a chemical synthesis designed to inhibit the kinase activity associated with RIPK1.

Formule : C₂₀H₁₇F₂N₅O₂

Degré de pureté : Min. 95%

Masse moléculaire : 397.38 g/mol

Ref: 3D-XPC84943